FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of ...
If you are wondering whether Geron’s current share price reflects its true worth, you are not alone. The stock’s recent moves have put valuation firmly in the spotlight. Over the last 7 days the share ...
In early March 2026, Geron Corporation filed a universal shelf registration covering common stock, preferred stock, debt securities and warrants, and registered an at-the-market follow-on equity ...
Geron Corporation (NASDAQ:GERN) is one of the 13 Best American Penny Stocks to Invest In. On January 29, TD Cowen analyst ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
With significant hedge fund interest and a share price under $10, Geron Corporation (NASDAQ:GERN) secures a spot on our list of the 11 Best Single Digit Stocks to Buy According to Hedge Funds. Geron ...
We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Geron Corporation (NASDAQ:GERN) stands against other best low priced ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 522,000 ...
Wall Street expects a year-over-year increase in earnings on higher revenues when Geron (GERN) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results